Incyte Corporation (INCY)
Automate Your Wheel Strategy on INCY
With Tiblio's Option Bot, you can configure your own wheel strategy including INCY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INCY
- Rev/Share 24.5981
- Book/Share 23.7706
- PB 4.4584
- Debt/Equity 0.0076
- CurrentRatio 3.1938
- ROIC 0.2057
- MktCap 20806280064.0
- FreeCF/Share 6.1177
- PFCF 17.3814
- PE 17.4469
- Debt/Assets 0.0056
- DivYield 0
- ROE 0.2983
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | INCY | Guggenheim | Neutral | Buy | -- | $125 | Nov. 3, 2025 |
| Downgrade | INCY | Oppenheimer | Outperform | Perform | -- | -- | Oct. 8, 2025 |
| Upgrade | INCY | Wells Fargo | Equal Weight | Overweight | -- | $89 | Aug. 6, 2025 |
| Initiation | INCY | Barclays | -- | Overweight | -- | $90 | Aug. 1, 2025 |
| Upgrade | INCY | Stifel | Hold | Buy | -- | $107 | June 16, 2025 |
| Downgrade | INCY | William Blair | Outperform | Market Perform | -- | -- | March 18, 2025 |
| Downgrade | INCY | Guggenheim | Buy | Neutral | -- | -- | March 18, 2025 |
| Initiation | INCY | UBS | -- | Neutral | -- | $77 | Dec. 17, 2024 |
| Initiation | INCY | Wolfe Research | -- | Outperform | -- | $84 | Oct. 1, 2024 |
| Downgrade | INCY | Truist | Buy | Hold | $83 | $74 | Sept. 18, 2024 |
News
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Negative
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.
Read More
Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation (NASDAQ:INCY ) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Conference Call Participants Tazeen Ahmad - Bank of America David Lebowitz - Citibank Jessica Fye - JPMorgan Salveen Richter - Goldman Sachs James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Marc Frahm - TD Cowen Kelly Shi - Jefferies Brian Abrams - …
Read More
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones.
Read More
About Incyte Corporation (INCY)
- IPO Date 1993-11-04
- Website https://www.incyte.com
- Industry Biotechnology
- CEO Herve Hoppenot
- Employees 2617